- Conditions
- COVID-19
- Interventions
- hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Newport Beach, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 329
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer
- Interventions
- BNT162b2 vaccine
- Biological
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- COVID-19, SARS-COV-2 Infection
- Interventions
- BNT162b2 (2025/2026 formulation)
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 27
- States / cities
- Palo Alto, California • San Diego, California • Homestead, Florida + 21 more
- Conditions
- SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Interventions
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 4,338 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
- Conditions
- COVID-19
- Interventions
- COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline)
- Drug
- Lead sponsor
- Invivyd, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (100 μg), CV0501 (200 μg)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Sacramento, California • Hollywood, Florida • Melbourne, Florida + 8 more
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
- Conditions
- Tinnitus
- Interventions
- DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine
- Drug
- Lead sponsor
- Leading Edge Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Ithaca, New York
- Conditions
- COVID-19
- Interventions
- CVXGA
- Biological
- Lead sponsor
- CyanVac LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- San Diego, California • Boise, Idaho • Sioux City, Iowa + 7 more
- Conditions
- Influenza, SARS-CoV-2
- Interventions
- mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more
- Conditions
- Covid19
- Interventions
- Opt-In (Call-Back), Opt-in (In-Bound), Standard Message, Clinician Endorsement, Scarcity, Opt-Out Framing, Phone Call
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 19,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b2, Placebo, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI, Combination (Bivalent) BNT162b2 and BNT162b2 OMI
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 16,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 139
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 99 more
- Conditions
- COVID-19, Healthy
- Interventions
- GLS-5310 (Group 1), GLS-5310 (Group 2), GLS-5310 (Group 3), GLS-5310 (Group 4)
- Drug
- Lead sponsor
- GeneOne Life Science, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Rockville, Maryland • Lincoln, Nebraska
- Conditions
- SARS-CoV Infection
- Interventions
- COVID-19 vaccine
- Biological
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- COVID-19 Respiratory Infection, SARS CoV 2 Infection, COVID-19 Vaccine
- Interventions
- CoV-RBD-scNP-001 and 3M-052-AF
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- COVID-19, Vaccination, Healthy Volunteer
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2050
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2, SARS-COV-2 Infection, Breakthrough Infection
- Interventions
- BNT162b2 (Tozinameran)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,277,747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- COVID-19 Infection
- Interventions
- Placebo Administration, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- Drug · Biological
- Lead sponsor
- GeoVax, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Claremont, California • Duarte, California • Thousand Oaks, California
- Conditions
- Covid19
- Interventions
- No video, Video Text
- Behavioral
- Lead sponsor
- NDRI-USA, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Herpes Zoster, Allergy and Immunology, Corona Virus Infection
- Interventions
- SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
- Biological · Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- COVID-19, COVID-19 Immunisation
- Interventions
- mRNA-1273
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Bethesda, Maryland • Seattle, Washington
- Conditions
- COVID-19, Vaccine Refusal
- Interventions
- Text Message, Motivational Interviewing, Electronic Educational Message with Tailored Questions/Prompts
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- COVID-19
- Interventions
- Active Intervention Group
- Behavioral
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- COVID-19 Vaccines
- Interventions
- High touch multi-pronged behavioral intervention
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- Not listed
- Enrollment
- 23,768 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Sykesville, Maryland • Elkhorn, Nebraska + 1 more